NCT01192802已完成4 期
Effect of Intestinal Helminths on Gut Microflora
适应症
干预措施
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 200
- 试验地点
- 1
- 主要终点
- parasite cleared and reduced up to 80% at day 42
研究概览
简要总结
Albendazole is a main anti-helminth, however there is a lack of data regarding its efficacy in the school children population. The aim of this study is to evaluate the efficacy of the albendazole one versus two and three doses, in school children infected with intestinal helminth.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- Single (Outcomes Assessor)
入排标准
- 年龄范围
- 4 Years 至 14 Years（Child）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •presence of intestinal helminths eggs in the stool
排除标准
- •allergy to imidazole derivate
- •No intestinal helminths
研究组 & 干预措施
1 dose, Albendazole , tablet
Active Comparator
干预措施: albendazole (Drug)
2 doses, albendazole, tablet
Active Comparator
1 tablet of 400 mg of albendazole per day for two consecutive days
干预措施: albendazole (Drug)
3 doses albendazole, 400mg, tablet
Active Comparator
干预措施: albendazole (Drug)
结局指标
主要结局
parasite cleared and reduced up to 80% at day 42
时间窗: 42 days
次要结局
- Prevalence of major gut bacteria(42 days)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
Assessment of Drug Efficacy of Local AlbendazoleHelminthiasisNCT02420574University Ghent679
已完成
4 期
A Multinational Trial of the Efficacy of Albendazole Against Soil-transmitted Nematode Infections in ChildrenInfections With Soil-Transmitted Helminths (STH)NCT01087099University Ghent1,750
已完成
不适用
Efficacy and involvement gut microbiota of atezolizumab plus bevacizumab therapy in patients with hepatocellular carcinoma.nresectable advanced hepatocellular carcinomaJPRN-UMIN000043934Kurume university34
进行中（未招募）
1 期
Effect of antifungals on the intestinal microbiome – a randomized, controlled, proof-of-concept trialot applicable - Healthy Volunteer studyCTIS2023-503710-69-00Amsterdam UMC50
已完成
4 期
EFESO - EFficacy Enterogermina Small Intestinal Bacterial OvergrowthIrritable Bowel SyndromeNCT00331994Sanofi250